Robert  Veltri, Ph.D.
Robert Veltri, Ph.D.

Associate Professor of Urology
Johns Hopkins Medical Institutions

The Brady Urological Research Institute, Park Building, 213, 600 North Wolfe Street , Baltimore, MD 21287-2101

Appointments: (410) 955-6380


Fax: (410) 502-7711


  Free Access to abstracts at PubMe

  1. Veltri RW and Kirk BE. An antiviral substance in the tissues of mice acutely infected with lymphocytic choriomeningitis virus. J Gen Virol., 10(1):17-27, 1971.
  2. Sprinkle PM, Veltri RW.  Microbiology of the middle ear and nasopharynx. Ann Otol Rhinol Laryngol. 1971 Jun;80(3):354-64.
  3. Veltri RW, Sprinkle PM, Keller SA, Chicklo JM. Immunoglobulin changes in a pediatric otolaryngic patient sample subsequent to T & A. J Laryngol Otol., 86(9):905-16, 1972.
  4. Veltri RW, Sprinkle PM, Keller SA, Chicklo JM. Ecological alterations of oral microflora subsequent to tonsillectomy and adenoidectomy. J Laryngol Otol., 86(9):893-903, 1972.
  5. Veltri RW and Sprinkle PM. Serous otitis media. Immunoglobulin and lysozyme levels in middle ear fluids and serum. Ann Otol Rhinol Laryngol., 82(3):297-301, 1973.
  6. Sprinkle PM and Veltri RW. The tonsil and adenoid dilemma: medical or surgical treatment? Otolaryngol Clin North Am, 1974; 84: 1142-48.
  7. Veltri RW, McClung JE and Sprinkle PM. Epstein-Barr Nuclear Antigens Carrying Lymphocytes in Human Palatine Tonsils.  Journal of General Virology 32: 455-460, 1976.
  8. Veltri RW and Sprinkle PM.  Secretory Otitis Media:  An Immune Complex Disease Annals of Otology, Rhinology and Laryngology 85: (Supplement 25), 135-139, 1976.
  9. Sloyer JL, PM, Veltri RW and Sprinkle PM. In vitro IgM antibody synthesis by human tonsil-derived lymphocytes. J Immunol., 111(1):183-8. 1973.
  10. Sprinkle PM and Veltri RW.  Quantitative alterations in the ecology of the oropharyngeal microflora subsequent to tonsillectomy and adenoidectomy. Trans Am Acad Ophthalmol. Otolaryngol., 78(2):ORL60-3, 1974.
  11. Sprinkle PM, Veltri RW and McClung JE. Epstein-Barr virus associated with episodes of recurrent tonsillitis. Arch Otolaryngol., 101(9):552-6, 1975.
  12. Sprinkle PM and Veltri RW. Secretory otitis media. An immune complex disease. Ann Otol Rhinol Laryngol., 85(2 Suppl 25 Pt 2):135-9, 1976.
  13. VeltriRW, Wainwright WH and Sprinkle PM. Immunological Identification of Epstein - Barr virus Early Antigen in a P3HR-1 Cell Extract. Journal of the National Cancer Institute 57: 245-253, 1976.
  14. Sprinkle PM, Veltri RW and Wade JA.  Clinical Significance of Viral Latency.  The Laryngoscope, Vol. LXXXVI, No. 12: 1815-1823, 1976.
  15. Sprinkle PM and Veltri RW. Recurrent adenotonsillitis: a new concept. Laryngoscope, 1976; 86: 58-63.
  16. Veltri RW, Mengoli HF, Maxim PE and Westfal SS. Isolation and Identification of Human Lung Tumor Associated Antigens.  Cancer Research 37: 1313-1322, 1977.
  17. Maxim PE,Veltri RW and Pusateri RJ.  Chronic Serous Otitis Media: An Immune Complex Disease.  Trans. Acad. Ophthalmology Otolaryngology 84:  234-238, 1977.
  18. Wainwright WH and Veltri RW.  Separation of the Complement Fixing and Early Antigens from Epstein-Barr Soluble Antigens.  Journal of the National Cancer Institute 58: 111-1113, 1977.
  19. Sprinkle PM and Veltri RW.  The Tonsils and Adenoids.  Clinical Otolaryngology 2: 153-167, 1977.
  20. Veltri RW, Heyl LW and Sprinkle PM. Epstein-Barr Virus Genome Carrying Lymphocyte Subpopulations of Human Palatine Tonsils.  Proc. Soc. Exp. Biol. Med. 156: 282-286, 1977.
  21. Mengoli HF, Veltri RW, Huang CW, Maxim PE and Sprinkle PM.  Cationic Proteins of Normal Lung Tissue and Lung Carcinoma.  3rd International Symposium on Detection and Prevention of Cancer.  Vol. II, Pages 645-655, 1977.
  22. Veltri RW, McClung JE and Sprinkle PM. Epstein-Barr Virus Antigens in Lymphocytes of Patients with Exudative Tonsillitis, Infectious Mononucleosis and Hodgkin's Disease.  Int. Journal of Cancer 21: 683-687, 1978.
  23. Veltri RW, Heyl LW, Sprinkle PM. Epstein-Barr genome carrying lymphocyte subpopulations of human palatine tonsils. Proc. Soc. Exp. Biol. Med. 1977; 156: 282-86.
  24. Maxim PE, Veltri RW, Sprinkle PM, Pusateri RJ. Soluble Immune Complexes in Sera from Head and Neck Cancer Patients:  A Preliminary Report: Trans Acad. Otolaryngol. 86: 428-432, 1978.
  25. Veltri RW, Sprinkle PM, Maxim PE, Theofilopoulos AN, Rodman SM, Kinney CL.  An Immune Monitoring Protocol for Patients with Carcinoma of the Head and Neck:  A Preliminary Report:  Ann. Otology, Rhinology and Laryngology, Vol. 87(5), Pg. 692-700, 1978.
  26. Veltri RW, Maxim PE, Mengoli HF and Burrell RG.  Search for New Human Tumor Associated Antigens in Carcinoma of the Lung.  3rd International Symposium on Detection and Prevention of Cancer.  Vol. II  Pages 625-644, 1978.
  27. Veltri RW, Maxim PE, Sprinkle PM, Flaherty DK and Kinney C. Immunopathogenesis of Serous Otitis Media, pgs. 29-34. In: Proceedings of the Second National Conference on Otitis Media.  R.J. Wiet and S.W.Coulthard eds., Ross Labs, Inc., Columbus 140: 22-32, 1979.
  28. Wainwright WH, Veltri RW, Sprinkle PM. Abrogation of Cell-Mediated Immunity by a Serum Blocking Factor (SBF) Isolated from Patients with Infectious Mononucleosis.  J. Infectious Diseases 140: 22-32, 1979.
  29. Veltri RW, McKolanis JR, Rockoff SD and McIntire KR.  Protein-A Antibody Binding (PAAB) Technique for Detection of Tumor Associated Membrane Antigen of Lewis Lung Carcinoma.  Int. J. Cancer, 25 (1): 141-145, 1980.
  30. Veltri, RW, Maxim PE, Boehlecke JM. Tumor-Associated Membrane Antigens (TAMA) Isolated from Human Squamous Cell carcinoma of the Lung. In Serologic Analysis of Human Cancer antigens, S. Rosenberg (Ed.) Academic Press Incorporated. New York, 1980.
  31. Maxim PE and Veltri RW.  Antigenic Mimicry Exhibited Between BCG and Human Neoplastic and Normal Tissue Extracts In: The Fifth Chicago Symposium on Cancer Immunology:  Experimental and Clinical, Elsevier- North Holland, 1980.
  32. Veltri RW, Maxim PE, and Boehlecke JM.  A Human tumor-Associated Membrane Antigen from Squamous-Cell Carcinoma of the Lung.  Br. J. Cancer, 41: 705-715, 1980.
  33. Baskies AM, Chretien PB, Maxim PE, Veltri RW, Wolf GT: Circulating immune complexes (CIC) correlate with levels of serum immune reactive proteins (IRP) and clinical tumor stage in head and neck squamous carcinoma (H&NSCa). Surgical Forum 31:526-527, 1980.
  34. Maxim PE, Veltri RW, and Westfall S.  Soluble Tumor Associated Markers in Lung Extracts.  Oncology, 38: 147-153, 1981.
  35. Sprinkle PM and Veltri RW. Epstein-Barr Virus infection and neoplasia. Otolaryngol Head and Neck Surg. 1981; Jul-Aug, 89:542-44.
  36. Veltri RW, Wilson WR and Sprinkle PM, Rodman SM and Ashenayi K. Implication of Viruses in Idiopathic Sudden Hearing Loss: Primary Infection or Reactivation of Latent Viruses?  American Academy of Otolaryngology, Oto H-N Surg. 89: 137-141, 1981.
  37. Veltri RW, Kikta VA, Wainwright WH and Sprinkle PM. Biological and Molecular Characterization of the IgG-Serum Blocking Factor (SBF-IgG) Isolated from Sera of Patients with EBV-Induced Infectious Mononucleosis. Journal of Immunology 127 (1): 320-328, 1981.
  38. Veltri RW, Raich PC, McClung JE, Shah SH Sprinkle PM. Lymphomatoid Granulomatosis and Epstein - Barr virus.  Cancer 50:1513-1517, 1982.
  39. Ockhizen R, Pandey JP, Veltri RW, Arlen M, Fudenberg H. Immunoglobulin Allotypes in Patients with Squamous Cell Carcinoma of the Head and Neck.  Cancer 49(10): 2021-2024, 1982.
  40. Brestel EP, Klingberg WG, Veltri RW, et al. Osteogenesis Imperfecta Tarda in a child with hyper-IgE syndrome. Am J Dis Child 136:774-776, 1982
  41. Boyd EL, McClung J.E., Veltri RW, Sprinkle P.M.  Early Antigen Titers in Pediatric Patients with Acute Cervical Lymphadenitis.  Otolaryngol. Head & Neck Surg. 90: 6-10, 1982.
  42. Grady, Dwight, McClung, J.E., Veltri RW, Sprinkle, P.M. and Veach, John S.  Association of Epstein - Barr virus with Acute Exudative Tonsillitis. Otolaryngol. Head & Neck Surg. 90: 11-15, 1982.
  43. Veltri RW, and Sprinkle P.M.  Immune Responses in Non-Acute, Non-Purulent Otitis Media with Effusion.  Proc. XIIth World Congress, Budapest, Hungary, 291-299, 1981.
  44. Veltri RW, Shah SH, McClung JE, Klingberg W.C. and Sprinkle, P.M. Epstein-Barr Virus, Fatal Infectious Mononucleosis and Hodgkin's Disease in Siblings.  Cancer 51: 509-520, 1983.
  45. McKolanis JR and Veltri RW.  Antibody Response to a Solublized Tumor Associated Membrane Antigen (TAMA) from the Murine Lewis lung Tumor. Cancer Immunology and Immunotherapy 15: 131-137, 1983.
  46. Wilson WR, Veltri RW, Laird N, and Sprinkle PM. Viral and Epidemiologic Studies of Idiopathic Sudden Hearing Loss.  Otolaryngol. Head and Neck Surgery 91: 653-658, 1983.
  47. Dowler  KW and Veltri RW.  In Vitro Neutralization of HSV-2: Inhibition by Binding of Normal IgG and Purified Fc to Virion Fc Receptor (FcR).  Journal of Medical Virology 13: 251-259, 1984.
  48. Veltri RW and Sprinkle PM.  Immunology of Otitis Media, Chapter 7, In: Immunobiology of the Head and Neck, Eds. J.F. Poliquin, A.F. Ryan, HJ.P. Harris.  College-Hill Press, San Diego, CA. pp. 137-156, 1984.
  49. Veltri RW. and Maxim PE. Tumor Immunity and Tumor Markers in Head and Neck Cancer.  In: Cancer Treatment and Research, Head and Neck Oncology. Ed. G.T. Wolf, Martin Nijhoff Publishers, Boston, MA. pp. 411-430, 1984.
  50. Kung VT, Maxim PE,Veltri RW and Martin FJ. Antibody-Bearing Liposomes Improve Agglutination of Latex Particles used in Clinical Diagnostic Assays.  Biochimica et. Biophysica Acta 839: 105-109, 1985.
  51. Veltri RW.  Immune Regulation in Carcinoma of the Head and Neck.  In: Head and Neck Cancer, Vol. 1: 564-567, (Chretien/Johns/Shedd/Strong/Word eds.), B.C. Decker Inc., Philadelphia, PA., 1985.
  52. Sprinkle PM and Veltri RW. Pathophysiology of serous otitis media. Am J Otol. 1986 Mar;7(2):113-8.
  53. VeltriRW, G. Fodor G, Liu CM, Woolverton CJ, Baseler MW.  A New Class of Synthetic Biological Response Modifiers: The Methylfurylbutyrolactones (NAFOCARE).  J. Biol. Res. Mod. 5:444-461, 1986.
  54. Woolverton CJ,Veltri RW, Snyder IS.  Stimulation of Human PMN In Vitro by a Succinimide Molecular Complex of Methylfurylbutyrolactones.  J. Biol. Res. Mod. 5(6):527-538, 1986.
  55. Maxim PE andVeltri RW.  Serum Ferritin as a Tumor Marker in Patients with Squamous Cell Carcinoma of the Head and Neck.  Cancer 57:305-311, 1986.
  56. Veltri RW, Rodman SM, Maxim PE, Baseler MW and Sprinkle PM. Immune Complexes, Serum Proteins, Cell-Mediated Immunity and Immune Regulation in Patients with Squamous Cell Carcinoma of the Head and Neck.  Cancer 57: 2295-2308, 1986.
  57. Baseler MW, Maxim PE, andVeltriRW  Circulating IgA Immune Complexes in Head and Neck Cancer, Nasopharyngeal Carcinoma, Lung Cancer, and Colon Cancer.  Cancer 59: 1727-1731, 1987.
  58. Fodor GB, Sussangkarn K, Arnold R, Mathelier H, Mohacsi T, Mujumdar R, Butterwick J, and Veltri RW. From methyglyoxal to new immunopotentiating ascorbic acid derivatives.  Acta Biochim. Biophys. Hung. 22(2-3): 165-179, 1987.
  59. Veltri RW, Partin AW, Epstein JI, Marley GM, Miller MC, et al.  Quantitative Nuclear Morphometry, Markovian Texture Descriptors, and DNA content Captured on a CAS-200 Image Analysis System, Combined with PCNA and Her-2/neu Immunohistochemistry for Prediction of Prostate Cancer Progression.  J. Cellular Biochemistry, Suppl. 19: 249-258, 1994.
  60. Hu Y, K Ashenayi, Veltri RW, R Hurst, and R Bonner. Neural Network Based Bladder Cancer Cell Classification. Proceedings of World Congress on Neural Networks, San Diego. Volume 1: 416-21, 1994.
  61. Bostwick DG, Burke HB, Wheeler TM, Chung LW, Bookstein R, Pretlow TG, Nagle RB, Montironi R, Lieber MM, Veltri RW, et al.  The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trialsJ Cell Biochem Suppl, 19:283-289, 1994.
  62. Ostrander GK, Blair JB, Stark BA, Marley GM, Bales WD, Veltri RW, Hinton DE, Okihiro M, Ortego LS, Hawkins WE.  Long-term primary culture of epithelial cells from rainbow trout (Oncorhynchus mykiss) liver. In Vitro Cell Dev Biol Anim, May;31(5):367-78, 1995.
  63. Carmichael MJ, Veltri RW, Partin AW, Miller MC, Walsh PC, Epstein JI.  Deoxyribonucleic Acid Ploidy Analysis as a Predictor of Recurrence Following Radical Prostatectomy for Stage T2 Disease.  J. Urology 153: 1015-1019, 1995.
  64. Berges RR, Vukanovic J Epstein JI, Carmichael, Cisek ML, Johnson DE, Veltri RW, Walsh PC, and Isaacs JT. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1: 473-480, 1995.
  65. McCue PA, Gomella LG, Veltri RW, Marley GM, Miller MC, Lattime EC.  Development of secondary structure, growth characteristics and cytogenetic analysis of human transitional cell carcinoma xenografts in scid/scid mice.  J Urol, Mar;155(3):1128-32, 1996.
  66. Veltri RW and Holzman D.  News article:  Algorithms vie for diagnostic role in prostate cancer.  JNCI  89(1): 1-4;15, 1997.
  67. An G, Luo G, Veltri RW, O'Hara SM.  Sensitive, nonradioactive differential display method using chemiluminescent detection.  Biotechniques, Mar;20(3):342-4, 346, 1996.
  68. Badalament RA, Miller MC, Peller PA, Young DC, Bahn DK, Kochie P, O'Dowd GJ, and Veltri RW.  An Algorithm for Predicting Non-organ Confined Prostate Cancer Using the Results Obtained From Sextant Core Biopsies and Prostate Specific Antigen Level.  J. Urology 156: 1375-80, 1996.
  69. Veltri RW, Miller MC, Partin AW, Coffey DS, and Epstein JI.  Ability to Predict Biochemical Progression Using Gleason Score and Computer-Generated Quantitative Nuclear Grade Derived from Cancer Cell Nuclei.  Urology 48: 685-91, 1996.
  70. Hurst RE, Roy JB, Kim KW, Veltri RW, Marley GM, Patton KP, Schackelford DL, Stein PL, and Parsons CL.  A Deficit of Chondroitin Sulfate Proteoglycans on Bladder Uroepithelium in Interstitial Cystitis.  Urology 48: 817-821, 1996.
  71. Marley, G.M., Miller MC, Kattan MC, Zhao G, Patton KP, Vessella RL, Wright Jr. GL, Schellhammer PF, and Veltri RW.  Free and Complexed Prostate Specific Antigen Serum Ratios to Predict Probability of Primary Prostate Cancer and Benign Prostatic Hyperplasia.  Urology 48(6A): 16-22, 1996.
  72. Weinstein, MH, Partin AW, Veltri RW, and Epstein JI. Neuroendocrine Differentiation in Prostate cancer.  Enhanced Prediction of Progression after Radical Prostatectomy.  Human Pathology 27: 683-87, 1996.
  73. von Eschenbach AC, Brawer MK, di Sant'Agnese PA, Humphrey PA, Mahran H, Murphy GP, Sebo TJ, Veltri RW. Exploration of new pathologic factors in terms of potential for prognostic significance and future applications. Cancer 78: 372-375, 1996.
  74. Veltri RW and Holzman D.  News article:  Algorithms vie for diagnostic role in prostate cancer.  JNCI  89(1): 1-4;15, 1997.
  75. Moreno JG, O'Hara SM, Long JP, Veltri RW, Ning X, Alexander AA, Gomella LG.  Transrectal ultrasound-guided biopsy causes hematogenous dissemination of prostate cells as determined by RT-PCR.  Urology  Apr;49:515-20, 1997.
  76. Hurst RE, Bonner RB, Ashenayi K, Veltri RW, and Hemstreet III GP.  Neural Net-based identification of cells expressing the p300 tumor-related antigen using fluorescence image analysis.  Cytometry  27: 36-42, 1997.
  77. O'Dowd GJ. Veltri RW, Orozco R, Miller MC, Osterling LP.  Update on the Appropriate Staging Evaluation for Newly Diagnosed Prostate Cancer.  J. Urology 158: 687-698, 1997
  78. Silberman, MA, Partin AW, Veltri RW, and Epstein JI. Tumor Angiogenesis Correlates with Progression after Radical Prostatectomy but Not with Pathologic Stage in Gleason Sum 5 to 7 Adenocarcinoma of the prostate.  Cancer 79:772-79, 1997.
  79. Slaton, JW, Dinney CPN, Veltri RW, Miller MC, Leibert M, O'Dowd GJ, and Grossman HB. DNA Ploidy enhances the cytologic prediction of Recurrent Transitional Cell Carcinoma of the Bladder.  J. Urology, 158: 806-811, 1997.
  80. Dinney CPN, Babkowski RC, Anteolo M, Perrotte P Liebert M, Zhuang H-Z, Palmer J, Veltri RW,  Katz R, and Grossman B. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. J Urology 1998; 160: 1285-90.
  81. Orozco R. O'Dowd GJ, Kunnel B, Miller MC, RW Veltri. Observations of Pathology Trends in 62,537 Prostate Biopsies Obtained from Urology Private Practices in the United States. Urology, 51: 186-195, 1998.
  82. Veltri RW, O'Dowd GJ, Orozco R, Miller MC. The Role of Biopsy Pathology, Quantitative Nuclear Morphometry, and Biomarkers in the Pre-operative Prediction of Prostate Cancer Staging and Prognosis.  Seminars in Urologic Oncology, 16(3): 106-107, 1998.
  83. Wojcik EM, Miller MC, O'Dowd GJ, Veltri RW, The Value of Computer Assisted Quantitative Nuclear Grading in Differentiation of Normal Urothelial Cells from Low and High Grade Transitional Cell Carcinomas.  Analytical and Quantitative Cytology and Histology, 20: 69-76, 1998.
  84. Wojcik EM, Miller MC, Wright BC, RW Veltri, O'Dowd GJ. Comparative Analysis of DNA Content in Polyoma virus-Infected Urothelial Cells, Urothelial Dysplasia and High Grade Transitional Cell Carcinoma.  Analytical and Quantitative Cytology and Histology, 19: 430-436, 1997.
  85. Veltri RW, Miller MC, Zhao G, Ng AY, Marley GM, Wright GL, Vessella RL, and Ralph DA.  Interleukin-8 (IL-8) serum levels in patients with benign prostatic hyperplasia and prostate cancer.  Urology 53: 139-47, 1999.
  86. An G, Cazares L, Luo G, Miller MC, Wright GL, and Veltri RW.  Differential expression of full length and a truncated Her-2/neu oncogene receptor in prostate cancer assessed using relative quantitative RT-PCR.  Mol Urol  2(4): 305-310, 1998.
  87. Veltri RW and Miller MC.  Free/Total PSA Ratios improve differentiation of benign and malignant disease of the prostate: Critical Analysis of two different test populations.  Urology 53(4): 736-45, 1999.
  88. Ng A, Bales WD, and Veltri RW.  Phenylbutyrate induced apoptosis and differential expression of BCL-2, BAX, p53, and FAS in human Prostate Cancer Cell Lines.  Analytical and Quantitative Cytology and Histology 22(1): 45-54, 2000.
  89. An G, Meka RCS, Bright SP, and Veltri RW.  Human prostate specific transglutaminase (pTGase) gene: Promoter cloning, tissue specific expression and down regulation in metastatic prostate cancer (CaP).  Urology 54: 1105-1111, 1999.
  90. Potter SR, Miller MC, Mangold LA, Jones KA, Epstein JI, Veltri RW and Partin AW.  Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy.  Urology 54: 791-795, 1999.
  91. Reckwitz T, Potter SR, Snow PB, Zhang Z, Veltri RW, and Partin AW.  Artificial neural networks in urology: Update 2000.  Prostate Cancer & Prostatic Diseases 2: 222-226, 1999.
  92. An Gang, Ng AY, Meka CSR, Luo G, Bright SP, Cazares L, Wright GL, and Veltri RW.  Cloning and characterization of UROC28, a novel gene overexpressed in prostate, breast and bladder cancers. Cancer Research 60: 7014-7020, 2000.
  93. O'Dowd GJ, Miller MC, Orozco R, and Veltri RW.  Analysis of repeat biopsy results within one year following a non-cancer diagnosis.  Urology 55 (4):553-59, 2000.
  94. Marks LS, Partin AW, Epstein JI, Tyler VE, Simon I, Macairan ML, Chan TL, Dorey FJ, Garris JB, Veltri RW, Santos PBC, Stonebrook KA, and DeKernion JB.  Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia.  J Urol  163(5): 1451-1456, 2000.
  95. Veltri RW, Miller MC, and An G.  Standardization, analytical validation, and quality control of intermediate endpoint biomarkers.  Urology  57(Suppl 4A), 164-70, 2001. 
  96. Veltri, RW, Partin, AW, and Miller, MC.  Quantitative nuclear grade (QNG): A new image analysis-based biomarker of clinically relevant nuclear structure alterations.  J. Cellular Biochemistry, 35: (Suppl), 151-157, 2000.
  97. O'Dowd GJ, Veltri RW, Miller MC, and Strum SB. The Gleason Score: A Significant Biologic Manifestation of Prostate Cancer Aggressiveness on Biopsy.  PCRI Insights, vol. 4, January, 2001.
  98. Veltri RW, Miller MC, Partin, AW, Poole Ed, and O'Dowd GJ.  Prediction of prostate cancer stage using quantitative biopsy pathology. Cancer 91: 2322-2328, 2001.
  99. Prescott JL, Montie J, Pugh TW, McHugh T, and Veltri RW.  Clinical sensitivity of p53 mutation detection in matched bladder tumor, bladder wash, and voided urine specimens.  Cancer 91: 2127-2135, 2001.
  100. Miller MC, O'Dowd GJ, Partin AW, and Veltri RW.  Contemporary use of complexed PSA and calculated Free PSA for Early Detection of Prostate Cancer: Impact of Changing Disease Demographics.  Urology 57: 1105-1111, 2001.
  101. Veltri RW, Miller MC, Mangold LA, O'Dowd GJ, Epstein JI, Partin AWPrediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.  J Urol 168(1):100-4, 2002.
  102. An G and Veltri. RW.  Differential display polymerase chain reaction using chemiluminescent detection.  In: Luminescence Biotechnology.  Eds. Knox Van Dyke, Christopher Van Dyke, and Karen Woodfork. CRC Press (Boca Raton, New York, and Washington, DC), 2002. 
  103. Veltri RW, Ph.D., M. Craig Miller. B.S., Gerard J. O'Dowd. M.D., and Alan W. Partin, M.D., Ph.D.  Impact of Age on Total and Complexed PSA Cutoffs in a Contemporary Referral Series of Men with Prostate Cancer.  Urology 60 (Suppl 4A): 47-52, 2002.
  104. Veltri RW, Marks LS, Miller MC, Bales WD, Fan J, MaCairan ML, Epstein JI, and Partin AW.  Saw Palmetto Alters Nuclear Measurements Reflecting DNA Content In Men With Symptomatic BPH: Evidence For A Possible Molecular Mechanism.  Urology 60: 617-22, 2002.
  105. Sawczuk IS, Pickens CL, Vasa UR,  Ralph DA, Ph.D., Norris KA, Miller MC, Ng AY, Grossman HB, and Veltri RW. DD23 Biomarker: A Prospective Clinical Assessment In Routine Urinary Cytology Specimens From Patients Being Monitored For TCC.  Urologic Oncology  7: 185-190, 2002.
  106. Gilbert SM, A Shabsigh, Sawczuk A, U Vasa, Angela Ng, C Pickens, K Norris, S Bright, GJ O'Dowd, MC Benson, CA Olsson, AS Sawczuk and RW Veltri,. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma (TCC) of the bladder in patients with a history of bladder cancer.  Urology  61: 539-543, 2003.
  107. Veltri RW, Manisha C, Miller MC, Poole EC, O'Dowd GJ and Partin AW.  Comparison of Logistic Regression and Neural Net Modeling for Prediction of Prostate Cancer Pathologic Stage.  Clin Chem. 48(10): 1828-34, 2002.
  108. Ellison LE, Cheli C, Bright S, Veltri RW, and Partin AW.  Cost-benefit analysis of total PSA, Free/Total PSA and complexed PSA for prostate cancer screening.  Urology 60 (Suppl 4A): 42-46, 2002.
  109. Haese A, Chaudhari M, Miller MC, Epstein JI, Graefen M, Hammerer P, Palisaar J, Huland H, Poole EC, O'Dowd GJ, Partin AW, and Veltri RW.  Quantitative biopsy pathology for the prediction of pathologically organ confined prostate cancer: A multiinstitutional validation study.  Cancer 97: 969-78,  2003.
  110. Presti JC, O'Dowd GJ, Miller MC, Mattu R, and Veltri RW.  Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in PSA and age-related cancer rates – results of a community multipartite study.  J Urology 169: 125-129, 2003.
  111. Gretzer MB, Partin AW, Chan DW, and Veltri RW.  Modern Tumor Marker Discovery in Urology: Surface Enhanced Laser Desorption and Ionization (SELDI). Reviews in Urology, 5(2): 81-89, 2003.
  112. Khan MA, Partin AW, Rittenhouse HG, Mikolajczyk SD, Sokoll LJ, Chan DW, and Veltri RW. Evaluation of Pro-PSA for the Early Detection of Prostate Cancer in Men with a total PSA Range of 4.0-10 ng/ml. J Urology  170: 723 -726, 2003.
  113. Khan MA, H. Carter HB, Epstein JI, Miller MC, Landis P, Walsh PC, Partin AW and Veltri RW. Can PSA derivatives and pathological parameters predict significant change in expectant management criteria for men with prostate cancer? J Urology 170: 2274-78, 2003.
  114. Khan MA, Walsh PC, Miller MC, Bales WD, Epstein JI, Mangold LA, Partin AW and Veltri RW. Quantitative alterations in nuclear structure predict prostate cancer distant metastasis and death in men with biochemical recurrence post-radical prostatectomy. Cancer, 98: 2583-9, 2003.
  115. Park J, Sokoll LJ, Bruzek DJ, Mangold LA, Gurganus R, Khan MA, Partin AW, Chan DW, and Veltri RW. Comparison of total PSA and derivative levels in a screening population of African-American, Caucasian, and Korean-American men. Clinical Prostate Cancer, 2: 173-76, 2004.
  116. Veltri RW, Khan MA, Miller MC, Epstein JI, Mangold LA, Walsh PC, Partin AW. Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate.  Clin Cancer Res., 10(10): 3465-73, 2004.
  117. Veltri RW, Partin AW, and Miller MC. Quantitative Nuclear Grade (QNG): The clinical applications of the quantitative measurement of nuclear structure using image analysis. In: Cancer Drug Discovery and Development. Gary J. Kelloff, Ernest T. Hawk and Caroline C. Sigman, Eds. The Humana Press Inc., Totowa, NJ, Volume 2, Chapter 6, 97-108, 2005.
  118. Gretzer MB, Chan DW, van Rootselaar CL, Rosenzweig JM, Dalrymple S, Mangold LA, Partin AW, and Veltri RW.  Proteomic analysis of Dunning Prostate Cancer Cell Lines with Variable Metastatic Potential using SELDI-TOF. Prostate. 60:(4):325-31, 2004.
  119. Veltri RW, Park Jae, Miller MC, Marks LS, Kojima M, van Rootselaar C, Khan MA, and Partin AW. Stromal-Epithelial Measurements of Prostate Cancer in Native Japanese and Japanese-American Men.  Prostate Cancer Prostatic Dis. 7(3):232-7, 2004.
  120. Marks LS, Kojima M, Demarzo A, Heber D, Bostwick DG, Qian J, Dorey FJ, Veltri RW, Mohler JL, Partin AW.  Prostate cancer in native Japanese and Japanese-American men: Effects of dietary differences on prostatic tissue. Urology, 64(4):765-71, 2004.
  121. Rogers CG, MA Khan, MC Miller, RW Veltri, and AW Partin. Natural history of progression in patients who fail to achieve an undetectable PSA following radical prostatectomy. Cancer, 2004; 101:2549–56.
  122. Bast RC, Jr., Lilja H, Urban N, Rimm DL, Fritsche H,  Gray J, Veltri RW, Klee G, Allen A,  Kim N, S Gutman S, Rubin MA and Hruszkewycz A.  Translational Crossroads for Biomarkers. Clin. Cancer Res. 2005; 11: 6103-6108.
  123. Veltri RW. MOLECULAR BIOLOGY OF SERUM BIOMARKERS FOR PROSTATE CANCER. In: Chapter 27, pp269-84.  Prostate Cancer: Principles and Practice, Edited by Roger Kirby, Alan Partin, Mark Feneley and J. Kellogg Parsons; 2006; Taylor and Francis Medical Books, Abingdon, OX14 4RN.
  124. Shiff C, Veltri R, Naples J, Quartey J, Otchere J, Anyan W, Marlow C, Wiredu E, Adjei A, Brakohiapa E, Bosompem K.  Ultrasound verification of bladder damage is associated with known biomarkers of bladder cancer in adults chronically infected with Schistosoma haematobium infection in Ghana. Trans. R. Soc. Trop. Med. Hyg. 2006; 100: 847-854.
  125. Veltri RW. Editorial comment. J Urol. 2006 Mar; 175(3): 944.
  126. Lee R, Localio R, Armstrong K, Malkowicz B, Schwartz JS, and The Free PSA Study Group. A Meta-Analysis of the Performance Characteristics of the Free Prostate-Specific Antigen Test. Urology 2006; 67: 762–768. [A total of 5401 subjects from our publication Urology 1999; 53: 736-754]
  127. Nielsen ME, Schaeffer EM, Veltri RW, Schoenberg MP and Getzenberg RH. Urinary Markers in the Detection of Bladder Cancer - What's New? Curr Opin Urol Rev.  2006; 16: 350-355.
  128. Parwani AV, Marlow C, DeMarzo A, Mikolajczyk SD, Rittenhouse HG, Veltri RW and Chan TY. Immunochemical Staining of Precursor Forms of Prostate cancer Antigen (ProPSA) in Metastatic Prostate cancer. Am J Surg Pathol. 2006; 10:1231-1236.
  129. Veltri RW, Khan MA, Marlow C, Miller MC, Mikolajczyk SD, Kojima M, Partin AW, Marks LS. Alterations in Nuclear Structure and Expression of ProPSA Predict Differences Between Native Japanese and Japanese American Prostate Cancer. Urology,2006; 68: 898-904.
  130. Veltri RW and Makarov DV. Nucleic Acid-Based Marker Approaches to Urologic Cancers. In: Seminars in Urologic Oncology, "Molecular Markers of Urologic Cancers", Ed. Robert G. Getzenberg, Elsevier, Philadelphia, PA. 2006; 24: 510-527.
  131. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS. Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism: A Randomized Controlled Trial. JAMA. 2006 Nov 15; 296(19):2351-2361.
  132. Berman D Rodriguez R and Veltri RW.  Campbell-Walsh Urology 9th Edition. Editor-in-Chief, Alan J. Wein, M.D., Ph.D (Hon). Eds. Kavoussi, LR, Novick AC, Partin AW, and Peters CA. Chapter 90,Vol 3; p2677-2726;  Development, Molecular Biology, and Physiology of the Prostate, Saunders-Elsevier, 170 S Independence Mall W, Suite 300E; Philadelphia, PA.
  133. Veltri RW, Marlow C, Khan MA, Miller MC, Epstein JI, and Partin AW. Significant Variations in Nuclear Structure Occur Between and Within Gleason Grading Patterns 3, 4, and 5 Determined by Digital Image Analysis. The Prostate. May 2007; 67(11):1202-1210.
  134. Malik G, Rojahn E, Ward MD, Gretzer MB, Partin AW, Semmes OJ, Veltri RW.  SELDI protein profiling of dunning R-3327 derived cell lines: Identification of molecular markers of prostate cancer progression.  The Prostate. 2007; 67(14):1565-1575.
  135. Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.  Am J Surg Pathol. 2007; 31(8):1246-55.
  136. Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A; Workshop Program Committee. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomarkers, 2007; 3(1):1-33.
  137. Makarov DV, Marlow C, Epstein JI, M. Miller MC, Landis P, Partin AW, Carter HB, and Veltri RW.  Predicting the Need for Treatment among Men with Low Grade, Low Stage Prostate Cancer Enrolled in a Program of Expectant Management with Curative Intent. The Prostate, 2008; 68:183 -189.
  138. Veltri RW, Ph.D., Miller MC, Isharwal S, Marlow C, BS., Makarov DV M.D., B.S and Partin AW, M.D., PhD. Prediction of PSA Recurrence in Men with 12 years Post-prostatectomy Follow-up.  Cancer Epidemiology Biomarkers Prev, 2008; 17(1):102– 110.
  139. Isharwal S, Miller MC, Marlow C, Makarov DV, Partin AW and Veltri RW. p300 (Histone Acetyltransferase) Biomarker Predicts Prostate Cancer Biochemical Recurrence and Correlates with Changes in Epithelia Nuclear Size and Shape. The Prostate, 2008; 68(10):1097-104.
  140. Isharwal S, Miller MC, B.S., Epstein JI, Mangold LA., Humphreys E, Partin AW, Veltri RW. Prognostic value of Her-2/neu and %DNA Index for Progression, Metastasis and Prostate Cancer-specific Death in Men with Long-Term Follow-up after Radical Prostatectomy.  Int. J Cancer, 2008; 123, 2636–2643.
  141. Veltri RW, Isharwal S, Miller MC, Epstein JI, Mangold, LA, Humphreys E, and Partin AW. Long-Term Assessment of Prostate Cancer Progression Free Survival: Evaluation of Pathological Parameters, Nuclear Shape and Molecular Biomarkers of Pathogenesis. The Prostate, 2008; 68:1806-1815.
  142. Isharwal S, Miller MC, B.S., Epstein JI, Mangold LA., Humphreys E, Partin AW, Veltri RW. Nuclear DNA Ploidy Measurements as a Surrogate to Biopsy Gleason Score for Preoperative Pathologic Stage Prediction. Submitted: Urology, 2009; 73(5):1092-7.
  143. Naples J, Isharwal S, Shiff C, Bosompem KM, and Veltri RW.  Clinical Utility of Squamous and Transitional Nuclear Structure Alterations induced by Schistosoma haematobium in chronically infected adults with bladder damage verified by Ultrasound in Ghana.  Anal Quant Cytol Histol 2009; 31:143–152.
  144. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphrey E, Han M, Partin AW, DeMarzo AM, Isaacs WB, Bova GS, and Luo J.  Ligand-independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone Refractory Prostate Cancer. Cancer Res. 2009; 69(1):16–22.
  145. Kortenhorst MSQ, Isharwal S, van Diest PJ, Chowdhury WH, Marlow C, Carducci MA, Rodriguez R, Veltri RW. Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo.  Mol Cancer Ther. 2009; 8(4): 802–808.
  146. Isharwal S, Makarov DV, Carter HB, Epstein JI, Partin AW, Landis P, Marlow C, and Veltri RW.  DNA content in the diagnostic biopsy benign-adjacent and cancer tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management program.  B JUI, 105, 2009; 329 – 333.
  147. Shiff C, Naples JM, Isharwal S, Bosompem KM, and Veltri RW. Non-invasive methods to detect schistosome-based bladder cancer: is the association sufficient? Trans R Soc Trop Med Hyg. 2010 Jan;104(1):3-5.
  148. Makarov DV, Isharwal S, Sokoll LJ, Marlow C, Epstein JI, Partin AW, Carter HB, and Veltri RW. proPSA Measurements in Serum and Tissue are Associated with Treatment Necessity Among Men Enrolled in Expectant Management for Prostate Cancer.  Clin Cancer Res 2009; 15(23):7316–21.
  149. Veltri RW, Isharwal S, Miller MC Epstein JI, and Partin AW. Nuclear Roundness Variance predicts Prostate Cancer Progression, Metastasis and Death: A prospective evaluation with up to 25 years of Follow-up after Radical Prostatectomy. The Prostate, 2010; 70: 1333–1339.
  150. Huang Y, Isharwal S, Haese A, Chun FK, Makarov DV, Feng Z, Han M, Humphreys E, Epstein JI, Partin AW and Veltri RW: Prediction of Patient-specific risk and percentile cohort risk of pathological stage using continuous PSA measurement, clinical stage and biopsy Gleason score. BJU Int. 2011 May ; 107(10): 1562–1569.
  151. Isharwal S, Makarov DV, Sokoll L, Landis P, Marlow C, Epstein JI, Partin AW, Carter HB, and Veltri RW: proPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict the need for prostate cancer treatment among men enrolled in a proactive surveillance program.  Urology, 2011; 77(3):763.e1-6.
  152. Ali S, Veltri R, Epstein JI, Christudass C, Madabhushi A: Adaptive Energy Selective Active Contour with Shape Priors for Nuclear Segmentation and Gleason Grading of Prostate Cancer. MICCAI, 2011: 661-669.
  153. Yoon, H. J.,  Li, C. C.,  Christudass, C. ,  Veltri, R.,  Epstein, J. I. and Zhang, Z.,  Cardinal          Multiridgelet- based Prostate Cancer Histological Image Classification for Gleason Grading,"   Proc. IEEE BIBM,  2011,  pp. 315-320.
  154. Tosoian JJ, Loeb S, Isharwal S, Landis P, Elliot DJ, Feng Z, Veltri R,  Epstein JI, Partin AW, Trock B, H. Carter B and Sokoll LJ.  [-2] proPSA is Associated with Biopsy Reclassification in Men on Active Surveillance for Prostate Cancer. Accepted for J Urology, 2012; 188: 1131-36.
  155. Veltri RW, Christudass CS, and Isharwal S. Nuclear morphometry, nucleomics and prostate cancer progression. Asian J Androl. 2012 May;14 (3):375-84. doi: 10.1038/aja.2011.148.
  156. Carter HB, Partin AW, Walsh PC, Trock BJ, Veltri RW, Nelson WG, Coffey DS, Singer EA, Epstein JI. Gleason Score 6 Adenocarcinoma: Should It Be Labeled As Cancer? J Clin Oncol. 2012 Oct 1. 
  157. Kim JJ, Bo Yin B, Christudass CS, Terada N, Rajagopalan K, Fabry B, Danielle Y. Lee DY, Shiraishi T, Robert H. Getzenberg  RH,  Veltri1 RW, An SS, & Mooney SM. Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer. J Cellular Biochemistry, J Cell Biochem. 2012 Nov 28. doi: 10.1002/jcb.24464. [Epub ahead of print]
  158. Zhong, X, Isharwal, S. Naples, JM, Shiff, C, Veltri, RW, Shao, C, Bosompem K, Sidransky, D and Hoque, MO. Hypermethylation of genes detected in urine from Ghanaian adults with bladder pathology associated with Schistosoma Haematobium infection. PLoS One. 2013; 8(3):e59089. doi: 10.1371/journal.pone.0059089. Epub 2013 Mar 18. PMID:  23527093.
  159. Ali S, Veltri R, Epstein JI, Christudass C, Madabhushi A. Cell Cluster Graph for Prediction of Biochemical Recurrence in Prostate Cancer Patients from Tissue Microarrays. Proc of SPIE Vol. 8676, 86760H-1.  doi: 10.1117/12.2008695
  160. Wei Y, Zou Z, Becker N, Anderson M, Sumpter R, Xiao G, Kinch L, Koduru P, Christudass CS, Veltri RW, Grishin NV, Peyton M, Minna J, Bhagat G, Levine B. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell. 2013 Sep 12;154(6):1269-84. doi: 10.1016/j.cell.2013.08.015.
  161. Lee G, Ali S, Veltri RW, Epstein JI, Christudass C, and Madabhushi A. Cell Orientation Entropy (COrE): Predicting Biochemical Recurrence from Prostate Cancer Tissue Microarrays. MICCAI, Sep.,2013, Nagoya, Japan.
  162. Veltri RW and Christudass CS. Nuclear morphometry, epigenetic changes, and clinical relevance in  prostate cancer.  Adv Exp Med Biol. 2014; 733: 77-99. doi: 10.1007/978-14899-8032-8 4. PMID: 2453344 [PubMed – in process]
  163. Kianercy A, Veltri RW, Pienta KJ. Critical transitions in a game theoretic model of tumour metabolism. Journal of the Royal Society Interface Focus, 2014; 
  164.  Veltri RW, Ph.D., Guangjing Zhu G, Lee G, Ali S, M.S., Madabhushi A. Histomorphometry of Digital Pathology: Case Study in Prostate Cancer. Frontiers of Medical Imaging; Chapter 15, edited by C.H. Chen.  September, 2014.
  165. Verdone J, Princy P, Veltri RW, Pienta K. Epithelial-mesenchymal transition in prostate cancer is associated with quantifiable changes in nuclear structure. The Prostate. 2015 Feb; 75(2):218-24. Epub 2014 Oct 18.DOI 10.1002/pros.22908 
  166. Ali  S, Veltri R, Epstein JI, Christhunesa Christudass CS, Madabhushi A. Selective Invocation of Shape Priors for Deformable Segmentation and Morphologic Classification of Prostate Cancer Tissue Microarrays. CMIG, December, 2014.
    • Veltri RW. Non-coding RNAs as biomarkers for metastatic prostate cancer. The Lancet Oncology, Volume 15, Issue 13, Pages 1412 - 1413, December 2014. 
      • Li J, Veltri RW, Yuan  Z, Christudass CS, Mandecki W. Macrophage Inhibitory Cytokine 1 Biomarker Serum Immunoassay in Combination with PSA is a More Specific Diagnostic Tool for Detection of Prostate Cancer. PLOS ONE, Accepted March 4, 2015. 
      • Yuan Tian Y, Choi C, Li Q, Rahmatpanah F, Chen X, Kim S, Veltri RW, Chia C, Zhang ZMercola D., Zhang H. Overexpression of periostin in stroma positively associated with aggressive prostate cancer. PLOS ONE, Accepted 2-26-15.
      • Lin WC, Li CC, Christudass CS, Epstein JI, Veltri RW. Curvelet-based Classification of Prostate Cancer Histological Images of Critical Gleason Scores.  ISBI, Accepted February, 2015.

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved. Disclaimer
Email: | 600 North Wolfe Street, Baltimore, Maryland 21287

urology second opinion urology second opinion